With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase ... Some leaders include Novo Nordisk, Eli Lilly, and Sanofi. These companies in the ...

recommended granting permission for the import and marketing of the tirzepatide Multi Dose Pen. According to SEC minutes, Eli Lilly must submit its Phase IV trial protocol to CDSCO within three months ...

The analyst in question upgraded NVO to "buy" from "neutral," citing strong demand for GLP-1 medications and calling it "the most exciting growth story in European pharma." Novo Nordisk stock has ...